ArticleInternational journal of general medicine2026
Elevated CA19-9 in IgG4-Related Autoimmune Pancreatitis: A Single-Center Retrospective Cohort Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics of IgG4-related disease patients with different serum IgG4 levels: A single-center retrospective study.The Journal of international medical research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgG4-related autoimmune pancreatitis (IgG4-AIP) is a rare autoimmune pancreatic disorder, with elevated carbohydrate antigen 19-9 (CA19-9) observed in some patients. Objective: This study aims to compare the clinical features of IgG4-AIP patients with elevated versus normal CA19-9 levels to clarify the clinical significance of CA19-9 in this condition. Methods: This study conducted a retrospective analysis of the clinical data of 41 patients with IgG4-AIP who underwent CA19-9 testing at Yichang Central People's Hospital from January 2019 to April 2025. In this study, the normal reference range for CA19-9 levels was defined as 0 to 39 U/mL. Results: Among the 41 patients with IgG4-AIP, 23 patients (56.10%) had normal CA19-9 levels, while 18 patients (43.90%) exhibited elevated CA19-9 levels. Patients with elevated CA19-9 levels were more likely to be misdiagnosed as having pancreatic tumors (55.56% vs. 13.04%) and had a higher incidence of bile duct involvement (88.89% vs. 26.09%), whereas the incidence of lymph node involvement (22.22% vs. 56.52%) was lower ( Conclusion: Patients with elevated CA19-9 levels in IgG4-AIP exhibit more complex clinical features. Clinicians should consider CA19-9 level differences when evaluating and managing IgG4-AIP patients to guide personalized diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.